Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Sanchez, Maria Victoria ^a,b   Ebensen, Thomas ^b   Schulze, Kai ^b   Cargnelutti, Diego ^a   Blazejewska, Paulina ^c   Scodeller, Eduardo A ^a   Guzmán, Carlos A ^b  

^a INSTITUTO ARGENTINO DE NIVOLOGÍA   (Argentina)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c Boehringer Ingelheim Veterinary Research Center GmbH and Co KG ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIS(3',5')CYCLIC DIMERIC ADENOSINE MONOPHOSPHATE; CYCLIC NUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; RECOMBINANT INFLUENZA NUCLEOPROTEIN; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MALE; MOUSE; NONHUMAN; PROTECTION; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; FEMALE; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 84925807864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104824     Document Type: Article

References (68)

1. Belongia E, Kieke B, Coleman L, Donahue J, Irving S, et al. (2008) Interim Within-Season Estimate of the Effectiveness of Trivalent Inactivated Influenza Vaccine - Marshfield, Wisconsin, 2007-08 Influenza Season. MMWR Morb Mortal Wkly Rep 18: 393-8.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44.
3. Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, et al. (2000) Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19: 217-226. (Pubitemid 30621515)
4. Brokstad KA, Eriksson J-C, Cox RJ, Tynning T, Olofsson J, et al. (2002) Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 185: 878-884. (Pubitemid 34274430)
5. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, et al. (1999) Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259: 256-261. (Pubitemid 29393375)
6. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, et al. (2000) A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19: 1180-1187. (Pubitemid 32010699)
7. O'Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, et al. (2012) Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice. MBio 3: e00120-12-e00120-12. doi:10.1128/mBio.00120-12.
8. Li CK, Rappuoli R, Xu X-N (2013) Correlates of protection against influenza infection in humans-on the path to a universal vaccine? Curr Opin Immunol 25: 470-476.
9. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, et al. (2009) M2e-based universal influenza A vaccine. Vaccine 27: 6280-6283.
10. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, et al. (2013) Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87: 10435-10446.
11. Vitelli A, Quirion MR, Lo C-Y, Misplon JA, Grabowska AK, et al. (2013) Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One 8: e55435.
12. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, et al. (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
13. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, et al. (2012) Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 55: 19-25.
14. Schotsaert M, Saelens X, Leroux-Roels G (2012) Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines 11: 949-962.
15. Effros RB, Doherty PC, Gerhard W, Bennink J (1977) Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 145: 557-568. (Pubitemid 8049609)
16. Yap KL, Ada GL, McKenzie IF (1978) Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273: 238-239. (Pubitemid 8331715)
17. Yewdell JW, Bennink JR, Smith GL, Moss B (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785-1789. (Pubitemid 15085262)
18. Taylor PM, Askonas BA (1986) Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58: 417-420. (Pubitemid 16097640)
19. McMichael AJ, Gotch FM, Noble GR, Beare PA (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17. (Pubitemid 13062888)
20. Kreijtz JHCM, de Mutsert G, van Baalen CA, Fouchier RAM, Osterhaus ADME, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166. (Pubitemid 351705225)
21. Grant E, Wu C, Chan K-F, Eckle S, Bharadwaj M, et al. (2013) Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol 91: 184-194.
22. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, et al. (1996) Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156: 3892-3900. (Pubitemid 26139942)
23. Guo L, Zheng M, Ding Y, Li D, Yang Z, et al. (2010) Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol 155: 1765-1775.
24. Rangel-Moreno J (2008) B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 180: 454-463.
25. Macleod MKL, David A, Jin N, Noges L, Wang J, et al. (2013) Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One 8: e61775.
26. Huang B, Wang W, Li R, Wang X, Jiang T, et al. (2012) Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J 9: 322.
27. Savard C, Laliberté-Gagné MÈ, Babin C, Bolduc M, Guérin A, et al. (2012) Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Vaccine 30: 2535-2542.
28. Patterson DP, Rynda-Apple A, Harmsen AL, Harmsen AG, Douglas T (2013) Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 7: 3036-3044.
29. Zhong W, Liu F, Dong L, Lu X, Hancock K, et al. (2010) Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections. PLoS One 5: e10583.
30. Hillaire MLB, Osterhaus ADME, Rimmelzwaan GF (2011) Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011: 939860.
31. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, et al. (2012) Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 122: 2847-2856.
32. Boonnak K, Subbarao K (2012) Memory CD4+ T cells: beyond "helper" functions. J Clin Invest 122: 2768-2770.
33. Price GE, Soboleski MR, Lo CY, Misplon J, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5: e13162.
34. Sekaly RP (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
35. Rose M, Zielen S, Baumann U (2012) Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 11: 595-607.
36. Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12: 592-605.
37. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53. (Pubitemid 40562303)
38. Falkeborn T, Bråve A, Larsson M, Akerlind B, Schröder U, et al. (2013) Endocine, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination. PLoS One 8: e70527.
39. Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A (2013) Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies. PLoS One 8: e69649.
40. Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, et al. (2013) A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses 7: 1181-1193.
41. Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, et al. (2011) Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29: 5210-5220.
42. Cargnelutti DE, Sanchez M V, Alvarez P, Boado L, Glikmann G, et al. (2012) Improved immune response to recombinant influenza nucleoprotein formulated with ISCOMATRIX. J Microbiol Biotechnol 22: 416-421.
43. Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, et al. (2011) Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 6: e26973.
44. Madhun AS, Haaheim LR, Nøstbakken JK, Ebensen T, Chichester J, et al. (2011) Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 29: 4973-4982.
45. Libanova R, Ebensen T, Schulze K, Bruhn D, Nörder M, et al. (2010) The member of the cyclic di-nucleotide family bis-(3′, 5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine 28: 2249-2258.
46. Ebensen T, Guzmán CA (2009) Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Adv Exp Med Biol 655: 171-188.
47. Ebensen T, Schulze K, Riese P, Morr M, Guzmán C A (2007) The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol 14: 952-958.
48. Ebensen T, Schulze K, Riese P, Link C, Morr M, et al. (2007) The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 25: 1464-1469. (Pubitemid 46074291)
49. LaMere MW, Lam H-T, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331-4339.
50. Lamere MW, Moquin A, Lee FE-H, Misra RS, Blair PJ, et al. (2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 85: 5027-5035.
51. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG (1992) Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 89: 6901-6905.
52. Mazanec MB, Coudret CL, Fletcher DR (1995) Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 69: 1339-1343.
53. Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, et al. (2013) Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS One 8: e61101.
54. Zhou D, Zhang Y, Li Q, Chen Y, He B, et al. (2011) Matrix protein-specific IgA antibody inhibits measles virus replication by intracellular neutralization. J Virol 85: 11090-11097.
55. Corthésy B, Benureau Y, Perrier C, Fourgeux C, Parez N, et al. (2006) Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 80: 10692-10699. (Pubitemid 44628915)
56. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, et al. (1998) Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9: 277-287. (Pubitemid 28400041)
57. Li C, Yang P, Sun Y, Li T, Wang C, et al. (2012) IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res 22: 528-538.
58. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, et al. (2009) IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182: 7353-7363.
59. Hamada H, Garcia-Hernandez M de la L, Reome JB, Misra SK, Strutt TM, et al. (2009) Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182: 3469-3481.
60. Wang X, Chan CCS, Yang M, Deng J, Poon VKM, et al. (2011) A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cell Mol Immunol 8: 462-468.
61. Kudva A, Scheller E V, Robinson KM, Crowe CR, Choi SM, et al. (2011) Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 186: 1666-1674.
62. Jaffar Z, Ferrini ME, Herritt LA, Roberts K (2009) Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol 182: 4507-4511.
63. Gopal R, Rangel-Moreno J, Fallert Junecko BA, Mallon DJ, Chen K, et al. (2014) Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection. Am J Pathol 184: 55-63.
64. Kai McKinstry K, Dutton RW, Swain SL, Strutt TM (2013) Memory CD4 T Cell-Mediated Immunity against Influenza A Virus: More than a Little Helpful. Arch Immunol Ther Exp (Warsz);61(5):341-53
65. Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280.
66. Wang W, Huang B, Jiang T, Wang X, Qi X, et al. (2012) Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One 7: e52488.
67. Hogan RJ, Zhong W, Usherwood EJ, Cookenham T, Roberts AD, et al. (2001) Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med 193: 981-986. (Pubitemid 32525871)
68. Sun K, Ye J, Perez DR, Metzger DW (2011) Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 186: 987-993.